Paper Details 
Original Abstract of the Article :
Thirty out-patients with chronic recurrent urinary tract infections, who had failed to respond to 10 days treatment with either pivmecillinam and/or amoxycillin, received a 3-month course of pivmecillinam at a dose of 200 mg, three times daily. Twenty-seven patients had bacteriuria due to Enterobact...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/030006058201000307

データ提供:米国国立医学図書館(NLM)

Pivmecillinam: A Long-Term Solution for Recurrent Urinary Tract Infections?

This study explores the vast desert of recurrent urinary tract infections (UTIs), a common and often frustrating condition for many. It examines the long-term effectiveness of pivmecillinam, a type of antibiotic, in treating these persistent infections.

Pivmecillinam Shows Promise, But Side Effects Exist

The study found that pivmecillinam was effective in eradicating the initial urinary pathogens in the majority of patients. However, some patients experienced reinfections during treatment. It's important to note that some patients also reported gastrointestinal side effects. While these side effects are not uncommon with antibiotics, they highlight the importance of carefully monitoring patients during treatment.

Navigating the Desert of UTIs: What To Keep in Mind

This study reminds us that UTIs are a persistent challenge for many, but there may be long-term treatment options available. However, it's important to be aware of potential side effects, and to closely monitor patients for any complications during treatment.

Dr. Camel's Conclusion

The research suggests that pivmecillinam might offer a potential oasis of relief for those battling persistent UTIs. However, like a desert traveler, it's essential to stay vigilant and address any potential side effects. Further research is needed to understand the optimal use of this antibiotic and to minimize the risk of reinfection.
Date :
  1. Date Completed 1982-09-24
  2. Date Revised 2017-02-14
Further Info :

Pubmed ID

6284565

DOI: Digital Object Identifier

10.1177/030006058201000307

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.